Clinical-Patient Studies

Journal of Neuro-Oncology

, Volume 82, Issue 1, pp 81-83

First online:

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

  • Marc C. ChamberlainAffiliated withDepartment of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute Email author 
  • , Michael J. GlantzAffiliated withDepartment of Neurology and Oncology, University of Massachusetts Medical Center
  • , Lisa ChalmersAffiliated withDepartment of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute
  • , Alixis Van HornAffiliated withDepartment of Neurology and Oncology, University of Massachusetts Medical Center
  • , Andrew E. SloanAffiliated withDepartment of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.

Keywords

Glioblastoma Temodar Radiotherpy